Skip to main content

Advertisement

Log in

An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Background

In 2009, the European Paediatric Study Group for Haemolytic Uraemic Syndrome (HUS) published a clinical practice guideline for the investigation and initial therapy of diarrhea-negative HUS (now more widely referred to as atypical HUS, aHUS). The therapeutic component of the guideline (comprising early, high-volume plasmapheresis) was derived from anecdotal evidence and expert consensus, and the authors committed to auditing outcome.

Methods

Questionnaires were distributed to pediatric nephrologists across Europe, North America, and the Middle East, who were asked to complete one questionnaire per patient episode of aHUS between July 1, 2009 and December 31, 2010. Comprehensive, anonymous demographic and clinical data were collected.

Results

Seventy-one children were reported with an episode of aHUS during the audit period. Six cases occurred on a background of influenza A H1N1 infection. Of 71 patients, 59 (83 %) received plasma therapy within the first 33 days, of whom ten received plasma infusion only. Complications of central venous catheters occurred in 16 out of 51 patients with a catheter in-situ (31 %). Median time to enter hematological remission was 11.5 days, and eight of 71 (11 %) patients did not enter hematological remission by day 33. Twelve patients (17 %) remained dialysis dependent at day 33.

Conclusions

This audit provides a snapshot of the early outcome of a group of children with aHUS in the months prior to more widespread use of eculizumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kavanagh D, Goodship TH (2010) Atypical hemolytic uremic syndrome. Curr Opin Hematol 17:432–438

    Article  PubMed  CAS  Google Scholar 

  2. Loirat C, Fremeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60

    Article  PubMed  PubMed Central  Google Scholar 

  3. Le Quintrec M, Roumenina L, Noris M, Fremeaux-Bacchi V (2010) Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 36:641–652

    Article  PubMed  Google Scholar 

  4. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531–536

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van der Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687–696

    Article  PubMed  Google Scholar 

  7. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric N (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400

    Article  PubMed  CAS  Google Scholar 

  9. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of R, Familial HT (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Witt V, Stegmayr B, Ptak J, Wikstrom B, Berlin G, Axelsson CG, Griskevicius A, Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J (2008) World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apher Sci 39:255–260

    Article  PubMed  Google Scholar 

  11. Mokrzycki MH, Balogun RA (2011) Therapeutic apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 26:243–248

    Article  PubMed  Google Scholar 

  12. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. New Engl J Med 360:544–546

    Article  PubMed  CAS  Google Scholar 

  13. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P (2011) Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 26:621–624

    Article  PubMed  Google Scholar 

  14. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707–710

    Article  PubMed  CAS  Google Scholar 

  15. Dorresteijn EM, van de Kar NC, Cransberg K (2012) Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 27:1193–1195

    Article  PubMed  PubMed Central  Google Scholar 

  16. Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L (2012) Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics 130:e1385–1388

    Article  PubMed  Google Scholar 

  17. Povey H, Vundru R, Junglee N, Jibani M (2013) Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol. doi:10.5414/CN107958

    PubMed  Google Scholar 

  18. Vilalta R, Lara E, Madrid A, Chocron S, Munoz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326

    Article  PubMed  PubMed Central  Google Scholar 

  19. Gulleroglu K, Fidan K, Hancer VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28:827–830

    Article  PubMed  Google Scholar 

  20. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New Engl J Med 368:2169–2181

    Article  PubMed  CAS  Google Scholar 

  21. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. New Engl J Med 361:345–357

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouviere C, Berard E, Salomon R, Fremeaux-Bacchi V, Niaudet P, Boyer O (2014) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 29:75–83

    Article  PubMed  Google Scholar 

  23. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal D (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475–486

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70:423–431

    PubMed  CAS  Google Scholar 

  25. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T, German-Austrian HUSSG (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407–415

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ (2013) Standardisation of the factor H autoantibody assay. Immunobiology 219:9–16

    Article  PubMed  Google Scholar 

  28. Coats MT, Murphy T, Paton JC, Gray B, Briles DE (2011) Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A. Microb Pathog 50:343–349

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Declaration of interests

The following authors declare interests. CMT and MB were scientific advisers to Thallion Pharmaceuticals. SJ, NvdK, GA, JVW, C. Licht, and MR have served on Advisory Boards for Alexion Pharmaceuticals. DK, C. Licht, and C. Loirat were the national coordinators of the multi-center Eculizumab trials in aHUS in Sweden, Canada, and France, respectively.

The European Paediatric Study Group for HUS is now known as HUS International and comprises pediatric nephrologists from Europe, North America, and the Middle East.

Contributors

Anne-Laure Adra1, Klaus Arbeiter2, Yelda Bilginer3, Heiko Billing4, Maria Bitsori5, Bernard Boudailliez6, Francisco de la Cerda – Ojeda7, Gérard Champion8, Amit Dagan9, Bradley Dixon, MD10, Philippe Eckart11, Israel Eisenstein12, Arnaud Garnier13, Clara Gomes14, Karsten Häffner15, Jerome Harambat16, Carol Inward17, Rafael Krmar18, Theresa Kwon19, Anne-Laure Lapeyraque20, Sebastian Loos21, Meeta Malik22, Mignon McCulloch23, David Milford24, Danko Milosevic25, Carla Nester26, François Nobili27, Pedro J Ortega28, Fotios Papachristou29, Antonia Peña - Carrión30, Ludmila Podracká31, Nikoleta Printza29, Bruno Ranchin32, Christopher Reid23, Caroline Rousset-Rouvière33, Rémi Salomon34, Anne-Laure Sellier-Leclerc35, James Springate36, Sophie Taque37, Despoina Tramma38, Sibylle Tschumi39, Ulrike Walden40, Kay Tyerman41, Aoife Waters42, Donald J Weaver Jr43

1Pediatric nephrology department, Hôpital A. de Villeneuve, Montpellier, France

2Medical University Vienna, Pediatric Nephrology, Vienna, Austria

3Hacettepe University Faculty of Medicine Pediatric Nephrology, Ankara, Turkey

4University Hospital Heidelberg, Pediatric Nephrology, Heidelberg, Germany

5Department of Pediatrics, University Hospital of Heraklion, Greece

6Department of Pediatrics, Centre Hospitalier Universitaire Nord, Amiens , France

7Virgen del Rocío Children´s Hospital, Division of Pediatric Nephrology, Seville, Spain

8Department of Pediatrics, Centre Hospitalier Universitaire, Angers, France

9Schneider Children's Hospital, Petach Tikvah (Tel Aviv University), Israel

10Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

11Department of Pediatrics, Centre Hospitalier Universitaire, Caen, France

12Myers Children's Hospital (Rambam Medical Center), Haifa (Technion University), Israel

13Pediatric nephrology department, Centre Hospitalier Universitaire Purpan, Hôpital des enfants, Toulouse, France

14Coimbra Pediatric Hospital, Division of Pediatric Nephrology, Coimbra, Portugal

15University Hospital Freiburg, Department of Pediatrics, Freiburg, Germany

16Department of Pediatrics, Centre Hospitalier Universitaire, Bordeaux, France

17Department of Paediatric Nephrology, Bristol Royal Hospital for Children, Bristol, UK

18Karolinska University Hospital Huddinge, Stockholm, Sweden

19Pediatric nephrology department Hôpital Robert Debré, Paris, France

20Centre Hospitalier Universitaire Sainte Justine, Montreal Quebec

21University Hospital Hamburg, Pediatric Nephrology, Hamburg, Germany

22Children's Renal & Urology Unit, Nottingham University Hospitals, Nottingham, UK

23Paediatric Nephro-urology Unit, Evelina Children’s Hospital, London, UK

24Birmingham Children’s Hospital, Birmingham, UK

25University Hospital Center Zagreb, Croatia

26The University of Iowa, Iowa City, Iowa, USA

27Pediatric Nephrology, Centre Hospitalier Universitaire, Besançon, France

28La Fe Hospital, Division of Pediatric Nephrology, Valencia, Spain

291st Department of Paediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

30La Paz Universitary Hospital, Division of Pediatric Nephrology, Madrid, Spain

31Children's Hospital of P.J. Safarik's University, 1st Pediatric Department, Košice, Slovakia

32Pediatric nephrology department, Hospices Civils de Lyon, Lyon, France

33Pediatric nephrology department, Hôpital de la Timone, Marseille, France

34Pediatric nephrology department, Hôpital Necker-Enfants Malades, Paris, France

35Pediatric nephrology department, Hôpital Trousseau, Paris, France

36Division of Nephrology, Women & Children's Hospital, Buffalo, New York, USA

37Department of Pediatrics, Centre Hospitalier Universitaire, Rennes, France

38Aristotle University of Thessaloniki, Thessaloniki, Greece

39Paediatric Nephrology, University Children's Hospital Bern, Switzerland

40Childrens Hospital Augsburg, Augsburg, Germany

41Department of Paediatric Nephrology, Leeds General Infirmary, Leeds, UK

42Department of Paediatric Nephrology, Great Ormond Street Hospital, London, UK

43Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, USA

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sally Johnson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Johnson, S., Stojanovic, J., Ariceta, G. et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29, 1967–1978 (2014). https://doi.org/10.1007/s00467-014-2817-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-014-2817-4

Keywords

Navigation